{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:04:46Z","timestamp":1783008286012,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13555-024-01305-x","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:22:44Z","timestamp":1732713764000},"page":"61-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians"],"prefix":"10.1007","volume":"15","author":[{"given":"Larisa","family":"Geskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ardig\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"1305_CR1","unstructured":"Orphanet. Classic mycosis fungoides. 2009. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=2584. Accessed Feb 2, 2024."},{"issue":"10","key":"1305_CR2","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"3","key":"1305_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/cancers15030746","volume":"15","author":"G Dobos","year":"2023","unstructured":"Dobos G, Lazaridou I, de Masson A. Mycosis fungoides and S\u00e9zary syndrome: microenvironment and cancer progression. Cancers (Basel). 2023;15(3):746. https:\/\/doi.org\/10.3390\/cancers15030746.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1305_CR4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/cells10102780","volume":"10","author":"A Pileri","year":"2021","unstructured":"Pileri A, Guglielmo A, Grandi V, et al. The microenvironment\u2019s role in mycosis fungoides and S\u00e9zary syndrome: from progression to therapeutic implications. Cells. 2021;10(10):2780. https:\/\/doi.org\/10.3390\/cells10102780.","journal-title":"Cells"},{"issue":"5","key":"1305_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","volume":"140","author":"EA Olsen","year":"2022","unstructured":"Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419\u201337. https:\/\/doi.org\/10.1182\/blood.2021012057.","journal-title":"Blood"},{"issue":"9","key":"1305_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/jdv.19237","volume":"37","author":"E Guenova","year":"2023","unstructured":"Guenova E, Ortiz-Romero PL, Poligone B, Querfeld C. Mechanism of action of chlormethine gel in mycosis fungoides. J Eur Acad Dermatol Venereol. 2023;37(9):1739\u201348. https:\/\/doi.org\/10.1111\/jdv.19237.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"32","key":"1305_CR7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/jco.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766\u201373. https:\/\/doi.org\/10.1200\/jco.2015.61.7142.","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv30-40. https:\/\/doi.org\/10.1093\/annonc\/mdy133.","journal-title":"Ann Oncol"},{"key":"1305_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2023. Eur J Cancer. 2023;195:113343. https:\/\/doi.org\/10.1016\/j.ejca.2023.113343.","journal-title":"Eur J Cancer"},{"key":"1305_CR10","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Primary cutaneous lymphomas. Version 1.2024. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx. Accessed Feb 2, 2024."},{"issue":"3","key":"1305_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496\u2013526. https:\/\/doi.org\/10.1111\/bjd.17240.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1305_CR12","doi-asserted-by":"publisher","first-page":"CD008946","DOI":"10.1002\/14651858.cd008946.pub3","volume":"7","author":"A Valipour","year":"2020","unstructured":"Valipour A, J\u00e4ger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020;7(7):CD008946. https:\/\/doi.org\/10.1002\/14651858.cd008946.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1305_CR13","unstructured":"Valchlor (mechlorethamine gel) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed Feb 2, 2024."},{"key":"1305_CR14","unstructured":"Ledaga [prescribing information]. Jerusalem, Israel: Rafa Laboratories Ltd.; 2020. https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum_17_462433720.pdf. Accessed Feb 2, 2024."},{"key":"1305_CR15","unstructured":"Ledaga [summary of product characteristics]. Dublin, Ireland: Helsinn Birex Pharmaceuticals Ltd.; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf. Accessed Feb 2, 2024."},{"issue":"1","key":"1305_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100069","volume":"2","author":"YT Chang","year":"2021","unstructured":"Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased chlormethine-induced DNA double-stranded breaks in malignant T\u00a0cells from mycosis fungoides skin lesions. JID Innov. 2021;2(1):100069. https:\/\/doi.org\/10.1016\/j.xjidi.2021.100069.","journal-title":"JID Innov"},{"issue":"suppl 1","key":"1305_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112994","volume":"190","author":"S Wind","year":"2023","unstructured":"Wind S, Rijneveld R, Grievink H, et al. Interstitial fluid immunophenotyping of early-stage mycosis fungoides patients after chlormethine treatment. Eur J Cancer. 2023;190(suppl 1):112994 (Oral presentation).","journal-title":"Eur J Cancer"},{"issue":"6","key":"1305_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","volume":"141","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Geskin LJ, Kim EJ, et al. Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Invest Dermatol. 2021;141(6):1601-4.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.12.009.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1305_CR19","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/09546634.2021.1967266","volume":"33","author":"H Prag Naveh","year":"2022","unstructured":"Prag Naveh H, Amitay-Laish I, Zidan O, et al. Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects. J Dermatolog Treat. 2022;33(4):2364\u201370. https:\/\/doi.org\/10.1080\/09546634.2021.1967266.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1305_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22(3):407\u201314. https:\/\/doi.org\/10.1007\/s40257-021-00591-x.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1305_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/jdv.18183","volume":"36","author":"E Papadavid","year":"2022","unstructured":"Papadavid E, Koumourtzis M, Nikolaou V, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol. 2022;36(10):1751\u20137. https:\/\/doi.org\/10.1111\/jdv.18183.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1305_CR22","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1095","volume":"102","author":"M Koumourtzis","year":"2022","unstructured":"Koumourtzis M, Lampadaki K, Dalamaga M, Papadavid E. Chlormethine gel is efficient and safe in mycosis fungoides skin lesions. Acta Derm Venereol. 2022;102:adv00730. https:\/\/doi.org\/10.2340\/actadv.v102.1095.","journal-title":"Acta Derm Venereol"},{"key":"1305_CR23","doi-asserted-by":"crossref","unstructured":"Teoli M, Cota C, Frascione P, Ardig\u00f2 M. Chlormethine gel in combination with retinoids for treatment of mycosis fungoides. EORTC-CLTG Annual Meeting. 21\u201323 September 2023, Leiden, the Netherlands. Poster P-209.","DOI":"10.1016\/j.ejca.2023.113096"},{"issue":"6","key":"1305_CR24","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","volume":"38","author":"K Lampadaki","year":"2021","unstructured":"Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T\u00a0cell lymphoma: three case reports. Adv Ther. 2021;38(6):3455\u201364. https:\/\/doi.org\/10.1007\/s12325-021-01721-x.","journal-title":"Adv Ther"},{"issue":"3","key":"1305_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-022-00681-6","volume":"12","author":"CV Alexander-Savino","year":"2022","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine\/Chlormethine Induced Dermatitis\u00a0Assessment Study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther (Heidelb). 2022;12(3):643\u201354. https:\/\/doi.org\/10.1007\/s13555-022-00681-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1305_CR26","unstructured":"Ardig\u00f2 M, Teoli M, Franceschini C. The use of concomitant chlormethine gel in a challenging case of mycosis fungoides cutaneous T-cell lymphoma. International Society for Cutaneous Lymphomas Scientific Meeting 2022. Poster RP26. https:\/\/cutaneouslymphoma.org\/wp-content\/uploads\/2022\/07\/RP26_Ardigo_CLGel_challenging_case_ISCL_30May22_UPDATE-Marco-Ardigo-2.pdf. Accessed Feb 2, 2024."},{"issue":"1","key":"1305_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multi-center trial testing the efficacy and safety of a novel 0.02% mechlorethamine gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25\u201332. https:\/\/doi.org\/10.1001\/2013.jamadermatol.541.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1305_CR28","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s13555-022-00831-w","volume":"12","author":"C Querfeld","year":"2022","unstructured":"Querfeld C, Nelson WW, Gor D, et al. Maintenance and concomitant therapy use with chlormethine gel among patients with stage\u00a0IA\/IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study. Dermatol Ther (Heidelb). 2022;12(12):2781\u201395. https:\/\/doi.org\/10.1007\/s13555-022-00831-w.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1305_CR29","doi-asserted-by":"publisher","first-page":"1308491","DOI":"10.3389\/fmed.2023.1308491","volume":"10","author":"M Ardig\u00f2","year":"2024","unstructured":"Ardig\u00f2 M, Nikbakht N, Teoli M, Gleason L, Crisan L, Querfeld C. Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases. Front Med (Lausanne). 2024;10:1308491. https:\/\/doi.org\/10.3389\/fmed.2023.1308491.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1305_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","volume":"157","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary syndrome. JAMA Dermatol. 2021;157(6):700\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0877.","journal-title":"JAMA Dermatol"},{"key":"1305_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/ddg.14462","volume":"19","author":"U Wehkamp","year":"2021","unstructured":"Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges. 2021;19:1057\u20139. https:\/\/doi.org\/10.1111\/ddg.14462.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1305_CR32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3911","volume":"101","author":"TJ Garcia-Saleem","year":"2021","unstructured":"Garcia-Saleem TJ, Stonesifer CJ, Khaleel AE, Geskin LJ. Management of mycosis fungoides with topical chlormethine\/mechlorethamine gel: a Columbia University Cutaneous Lymphoma Center experience. Acta Derm Venereol. 2021;101:adv00544. https:\/\/doi.org\/10.2340\/00015555-3911.","journal-title":"Acta Derm Venereol"},{"key":"1305_CR33","doi-asserted-by":"publisher","DOI":"10.1159\/000516138","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase\u00a02 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage\u00a0IA\u2013IIA mycosis fungoides. Dermatology. 2021. https:\/\/doi.org\/10.1159\/000516138.","journal-title":"Dermatology"},{"issue":"4","key":"1305_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther (Heidelb). 2021;11(4):1085\u2013106. https:\/\/doi.org\/10.1007\/s13555-021-00539-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1305_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40257-022-00687-y","volume":"23","author":"C Querfeld","year":"2022","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, et al. Chlormethine gel versus chlormethine ointment for treatment of patients with mycosis fungoides: a post-hoc analysis of clinical trial data. Am J Clin Dermatol. 2022;23(4):561\u201370. https:\/\/doi.org\/10.1007\/s40257-022-00687-y.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1305_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.clml.2022.02.002","volume":"22","author":"E Correia","year":"2022","unstructured":"Correia E, Krishnasamy S, Suriano JG, et al. Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2022;22(8):581\u20138. https:\/\/doi.org\/10.1016\/j.clml.2022.02.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1305_CR37","doi-asserted-by":"publisher","first-page":"1298988","DOI":"10.3389\/fmed.2023.1298988","volume":"10","author":"L Geskin","year":"2024","unstructured":"Geskin L, Querfeld C, Hodak E, et al. Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides. Front Med (Lausanne). 2024;10:1298988. https:\/\/doi.org\/10.3389\/fmed.2023.1298988.","journal-title":"Front Med (Lausanne)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01305-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01305-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01305-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:30:23Z","timestamp":1738380623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01305-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01305-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Larisa Geskin: Consulting fees, payment or honoraria, and\/or research grant support: Helsinn, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Recordati Rare Diseases, Regeneron, Sanofi, Merck and Soligenix, UpToDate, and Medscape; patent on method to diagnose cutaneous lymphoma; leadership role: International Society for Cutaneous Lymphomas and United States Cutaneous Lymphoma Consortium; stock\/stock options: CelSyntec, Inc. Neda Nikbakht: Advisory board: Helsinn and Kyowa Kirin. Christiane Querfeld: Steering Committee\/Advisory Board: Helsinn, Kyowa Kirin; Investigator: Helsinn, Celgene (Bristol Myers Squibb), Kyowa Kirin; Research Grants: Celgene, Helsinn. Emmilia Hodak: Scientific advisory board: Actelion, Helsinn, Recordati Rare Diseases, Takeda, Vidac; speakers\u2019 bureau: Helsinn, Rafa, Takeda. Evangelia Papadavid: Lecturer: Helsinn, Mallinckrodt, AbbVie, Janssen, Novartis. Marco Ardig\u00f2: Lecturer: Helsinn, Kyowa Kirin, Takeda, VivaScope, Almirall, Recordati Rare Diseases. Ulrike Wehkamp: Clinical investigator: miRagen, Kyowa Kirin, Innate Pharma, 4SC. Honoraria for lectures\/advisory boards: Helsinn, Kyowa Kirin, MSD, Takeda, Mundipharma, Galderma, Stemline. Martine Bagot: Advisory board: Helsinn-Recordati, Kyowa Kirin, Takeda, Innate Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This manuscript does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}